Benefit of primary percutaneous coronary interventions in the elderly with ST segment elevation myocardial infarction.
Age Factors
Aged
Aged, 80 and over
Comorbidity
Female
Humans
Male
Percutaneous Coronary Intervention
/ adverse effects
Pulmonary Edema
/ mortality
Recurrence
Registries
Risk Assessment
Risk Factors
ST Elevation Myocardial Infarction
/ diagnostic imaging
Shock, Cardiogenic
/ mortality
Spain
Time Factors
Treatment Outcome
acute coronary syndrome
coronary intervention (PCI)
stemi
Journal
Open heart
ISSN: 2053-3624
Titre abrégé: Open Heart
Pays: England
ID NLM: 101631219
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
16
09
2019
revised:
21
04
2020
accepted:
02
06
2020
entrez:
5
8
2020
pubmed:
5
8
2020
medline:
22
12
2020
Statut:
ppublish
Résumé
Primary percutaneous coronary intervention (P-PCI) has demonstrated its efficacy in patients with ST segment elevation myocardial infarction (STEMI). However, patients with STEMI ≥75 years receive less P-PCI than younger patients despite their higher in-hospital morbimortality. The objective of this analysis was to determine the effectiveness of P-PCI in patients with STEMI ≥75 years. We included 979 patients with STEMI ≥75 years, from the Of the included patients, 81.5 % received P-PCI. The matching provided two groups of 169 patients with and without P-PCI. Compared with its non-performance, P-PCI presented a composite event OR adjusted by PS of 0.55 (95% CI 0.34 to 0.89). Receiving a P-PCI was significantly associated with a reduced risk of major intrahospital complications in patients with STEMI aged 75 years or older.
Identifiants
pubmed: 32747454
pii: openhrt-2019-001169
doi: 10.1136/openhrt-2019-001169
pmc: PMC7402007
pii:
doi:
Types de publication
Comparative Study
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Eur Heart J. 2018 Jan 7;39(2):119-177
pubmed: 28886621
Rev Esp Cardiol (Engl Ed). 2014 Jul;67(7):564-73
pubmed: 24952397
Rev Esp Cardiol (Engl Ed). 2017 Feb;70(2):81-87
pubmed: 27840148
Circulation. 2007 May 1;115(17):2340-3
pubmed: 17470708
Rev Clin Esp. 2015 May;215(4):195-203
pubmed: 25499670
Eur Heart J. 2016 Apr 21;37(16):1304-11
pubmed: 26757786
Eur Heart J. 2010 Mar;31(6):634-6
pubmed: 19965864
Stroke. 2000 Aug;31(8):1802-11
pubmed: 10926938
J Am Coll Cardiol. 2012 Dec 18;60(24):2481-9
pubmed: 22858390
Catheter Cardiovasc Interv. 2014 Apr 1;83(5):686-701
pubmed: 24282083
Pharm Stat. 2011 Mar-Apr;10(2):150-61
pubmed: 20925139
Eur Heart J. 2011 Jan;32(1):51-60
pubmed: 20971744
Eur Heart J. 2018 Feb 14;39(7):508-579
pubmed: 29190377
Rev Esp Cardiol (Engl Ed). 2013 Jun;66(6):472-81
pubmed: 24776050
Eur Heart J. 2014 Jun 14;35(23):1551-8
pubmed: 24644310
Circulation. 2007 May 15;115(19):2570-89
pubmed: 17502591
PLoS One. 2017 Feb 2;12(2):e0168726
pubmed: 28151965
Rev Esp Cardiol. 2008 Aug;61(8):803-16
pubmed: 18684363
Open Heart. 2015 Jun 24;2(1):e000235
pubmed: 26196017
Eur Heart J. 2014 Aug 1;35(29):1957-70
pubmed: 24419804
J Am Coll Cardiol. 2013 Jan 29;61(4):e78-e140
pubmed: 23256914
Am J Cardiol. 1967 Oct;20(4):457-64
pubmed: 6059183
Rev Esp Cardiol (Engl Ed). 2019 Aug;72(8):691-693
pubmed: 30553803
Rev Esp Cardiol (Engl Ed). 2017 Mar;70(3):155-161
pubmed: 27600863
PLoS One. 2016 Nov 3;11(11):e0165672
pubmed: 27812152
Int J Cardiol. 2017 Dec 15;249:83-89
pubmed: 29121766
BMJ Open. 2012 Feb 16;2(1):e000540
pubmed: 22344538
Rev Esp Cardiol. 2003 Dec;56(12):1165-73
pubmed: 14670268
Am J Cardiol. 2013 Jul 1;112(1):1-7
pubmed: 23540546
Am J Cardiol. 2009 Jan 15;103(2):170-4
pubmed: 19121431
Eur Heart J. 2011 Jul;32(14):1704-8
pubmed: 21362706